Table 2.

Clinical outcomes at 18 months after randomisation. Values are numbers (percentages) unless stated otherwise

Outcome	SAPT (n=433)	DAPT (n=437)	Hazard ratio SAPT v DAPT (95% CI)	P value
Primary endpoint
Composite*	21 (4.8%)	29 (6.6%)	0.73 (0.41 to 1.27)	0.26 0.004 for non-inferiority
Secondary endpoints
Composite†	14 (3.2%)	19 (4.3%)	0.75 (0.37 to 1.49)	0.40
Death:	3 (0.7%)	6 (1.4%)	0.51 (0.13 to 2.02)	0.33
Cardiac	2 (0.5%)	4 (0.9%)	0.51 (0.09 to 2.76)	0.43
Myocardial infarction	8 (1.8%)	8 (1.8%)	1.02 (0.38 to 2.71)	0.97
Revascularisation:	13 (3.0%)	17 (3.9%)	0.87 (0.42 to 1.83)	0.72
Urgent	8 (1.8%)	13 (3.0%)	0.83 (0.34 to 1.99)	0.67
Target lesion	4 (0.9%)	4 (0.9%)	1.02 (0.25 to 4.06)	0.98
Target vessel, non-target lesion	2 (0.5%)	5 (1.1%)	0.40 (0.08 to 2.08)	0.28
Non-target vessel	6 (1.4%)	10 (2.3%)	0.76 (0.26 to 2.18)	0.61
Stent thrombosis	3 (0.7%)	4 (0.9%)	0.76 (0.17 to 3.39)	0.72
Stroke	3 (0.7%)	3 (0.7%)	1.02 (0.21to 5.03)	0.99
Bleeding:	3 (0.7%)	5 (1.1%)	0.61 (0.15 to 2.53)	0.49
Thrombolysis in myocardial infarction major	1 (0.2%)	2 (0.5%)	0.51 (0.05 to 5.57)	0.58
BARC type 3	2 (0.5%)	4 (0.9%)	0.50 (0.09 to 2.75)	0.43
Target lesion failure‡	5 (1.2%)	8 (1.8%)	0.63 (0.21 to 1.93)	0.42
Hospital stay:	33 (7.6%)	38 (8.7%)	0.92 (0.58 to 1.48)	0.74
Cardiac	26 (6.0%)	33 (7.6%)	0.84 (0.50 to 1.42)	0.52
Chest pain	11 (2.5%)	13 (3.0%)	0.93 (0.41 to 2.10)	0.85

^*All cause mortality, any myocardial infarction, any revascularization, stroke, and thrombolysis in myocardial infarction major bleeding (net adverse clinical events).

^†All cause mortality, any myocardial infarction, stent thrombosis, stroke, and thrombolysis in myocardial infarction major bleeding.

^‡Cardiac death, target lesion revascularization, or target lesion myocardial infarction.

BARC=Bleeding Academic Research Consortium